DBCO-PEG4-Val-Cit-PAB-MMAE CAS:2129164-91-4 is an advanced precursor for antibody-drug conjugates (ADCs), featuring a dibenzocyclooctyne (DBCO) PEG4 moiety, a protease-sensitive valine-citrulline (Val-Cit) dipeptide, a para-aminobenzyl carbamate (PABC) linker, and a potent synthetic antineoplastic agent, monomethyl auristatin E (MMAE). The DBCO group is widely used in copper-free Click Chemistry reactions, enabling efficient conjugation.
Introduction to the application:
In pharmaceutical research and development, DBCO-PEG4-Val-Cit-PAB-MMAE plays a vital role in the design of targeted ADCs for cancer therapy. The innovative drug-linker complex facilitates the precise delivery of the powerful MMAE cytotoxic agent to cancer cells, minimizing off-target effects and enhancing treatment efficacy. By attaching the complex to a monoclonal antibody (MAB), it is directed specifically toward cancer cells. The protease-sensitive Val-Cit dipeptide and PABC linker ensure stability in the bloodstream and selective release within tumor cells, contributing to the development of safer and more effective anticancer treatments.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.